This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
by Debanjana Dey
Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
HIMSPositive Net Change LFMDNegative Net Change DOCSPositive Net Change
medical medical-devices
Should You Buy Allegro MicroSystems, Inc. (ALGM) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ALGMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CVS Health's MBR Improves: Can It Sustain Amid Elevated Cost Trends?
by Moumi Mondal
CVS posts its first favorable MBR in quarters, but elevated cost trends test its ability to sustain the gains.
UNHPositive Net Change CVSPositive Net Change ELVNegative Net Change
medical medical-devices
DOCS Boosts Client Retention via Workflow Integration and AI Tools
by Debanjana Dey
Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.
VEEVPositive Net Change GDRXNegative Net Change DOCSPositive Net Change
medical medical-devices
Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, the macroeconomic factors, such as weakened global demand, persist.
ANGOPositive Net Change XRAYPositive Net Change CVSPositive Net Change ITGRNegative Net Change
medical medical-devices
ISRG Margin Outlook Dips on Tariffs, Demand Signals Stay Strong
by Harshit Gupta
Intuitive Surgical trims margin outlook on tariff headwinds, but strong procedure growth and financial resilience bolster its long-term case.
MDTPositive Net Change ISRGPositive Net Change ZBHPositive Net Change
medical medical-devices
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
IMABNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?
by Zacks Equity Research
PBH rides strong on e-commerce gains and brand innovations, but debt load and forex risks cast a shadow on future growth.
CORPositive Net Change PBHNegative Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
by Moumi Mondal
HOLX grapples with global headwinds, but growth in Diagnostics and Breast Health service lifts confidence.
MDTPositive Net Change HOLXNegative Net Change QGENNegative Net Change
medical medical-devices
BrightSpring Soars to All-Time High on Quality Strength: Still a Buy?
by Urmimala Biswas
BTSG stock hits an all-time high with a 120% gain as soaring quality ratings and strong Q1 results fuel investor confidence.
AMEDPositive Net Change OPCHPositive Net Change BTSGPositive Net Change
earnings-outlook earnings-report healthcare medical medical-devices
Sonic Automotive (SAH)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SAHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
nLight (LASR) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
LASRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Vistra Corp. (VST)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
VSTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
by Zacks Equity Research
BRKR strengthens its MS-based metabolomics platform with the biocrates deal, boosting investor sentiment.
CORPositive Net Change BRKRNegative Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?
by Urmimala Biswas
Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?
AZNNegative Net Change IRTCNegative Net Change SOPHNegative Net Change TEMPositive Net Change
artificial-intelligence earnings-report healthcare medical medical-devices smart-health
ZimVie Stock Gains Following the Launch of RealGUIDE Software Suite
by Zacks Equity Research
ZIMV launches RealGUIDE Software Suite and Implant Concierge in Japan to boost digital dental workflows.
ANGOPositive Net Change CVSPositive Net Change ITGRNegative Net Change ZIMVPositive Net Change
medical medical-devices
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
by Zacks Equity Research
Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.
ANGOPositive Net Change PENPositive Net Change ITGRNegative Net Change
medical-devices
Contango ORE, Inc. (CTGO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CTGONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Par Petroleum (PARR) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
PARRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hologic Climbs 13% in a Month: How Should You Play the Stock?
by Moumi Mondal
HOLX up 13% over the last month, supported by a rejected $16.7 billion buyout offer and new BCI data. What's the investment outlook?
BDXNegative Net Change HOLXNegative Net Change EXASNegative Net Change
medical medical-devices
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
by Zacks Equity Research
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
ANGOPositive Net Change CVSPositive Net Change NVCRNegative Net Change ITGRNegative Net Change
medical medical-devices
Dave Inc. (DAVE) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DAVEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
by Urmimala Biswas
PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.
PENPositive Net Change ANGOPositive Net Change ITGRNegative Net Change
artificial-intelligence medical medical-devices smart-health
Intuitive Surgical Stock Gains 12.7% QTD: Is it Still a Buy Now?
by Indrajit Bandyopadhyay
ISRG's shares seem to recover after declining more than 30% from its all-time high. Is it the right time to invest?
JNJPositive Net Change MDTPositive Net Change ISRGPositive Net Change
medical medical-devices
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
by Moumi Mondal
TEM's rapid growth and cost discipline are paving the way for a positive adjusted EBITDA in 2025.
MYGNNegative Net Change GHPositive Net Change TEMPositive Net Change
medical medical-devices